Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Harding

Showing results (871-880 of 946) with videos related to

Pageof 95
Sort By:
Cancer|August 6, 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experienceJason J Luke, Margaret K Callahan, Michael A Postow, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 6, 2019
First-in-Humans Imaging with <sup>89</sup>Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion TargetingNeeta Pandit-Taskar, Michael A Postow, Matthew D Hellmann, et al.
The Journal of Antimicrobial Chemotherapy|March 14, 2024
Empirical antimicrobial prescribing for pyelonephritis in patients discharged from 15 US Emergency Departments: an opportunity for improvementMegan A Rech, Brett A Faine, Alan E Gross, et al.
Cancer|August 19, 2020
Clinical implications of drug-induced liver injury in early-phase oncology clinical trialsSebastian P Mondaca, Dazhi Liu, Jessica R Flynn, et al.
The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.
Investigational New Drugs|March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxelLillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Science Advances|July 19, 2024
Huntingtin is an RNA binding protein and participates in <i>NEAT1</i>-mediated paraspecklesManisha Yadav, Rachel J Harding, Tiantian Li, et al.
Scientific Reports|November 14, 2023
Gut inflammation associated with age and Alzheimer's disease pathology: a human cohort studyMargo B Heston, Kendra L Hanslik, Katie R Zarbock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2018
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune TherapiesJames J Harding, Subhiksha Nandakumar, Joshua Armenia, et al.
The Lancet. Oncology|June 5, 2023
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b studyJames J Harding, Jia Fan, Do-Youn Oh, et al.
Pageof 95

Showing results (871-880 of 946) with videos related to

Sort By:
Pageof 95
Cancer|August 6, 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experienceJason J Luke, Margaret K Callahan, Michael A Postow, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 6, 2019
First-in-Humans Imaging with <sup>89</sup>Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion TargetingNeeta Pandit-Taskar, Michael A Postow, Matthew D Hellmann, et al.
The Journal of Antimicrobial Chemotherapy|March 14, 2024
Empirical antimicrobial prescribing for pyelonephritis in patients discharged from 15 US Emergency Departments: an opportunity for improvementMegan A Rech, Brett A Faine, Alan E Gross, et al.
Cancer|August 19, 2020
Clinical implications of drug-induced liver injury in early-phase oncology clinical trialsSebastian P Mondaca, Dazhi Liu, Jessica R Flynn, et al.
The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.
Investigational New Drugs|March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxelLillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Science Advances|July 19, 2024
Huntingtin is an RNA binding protein and participates in <i>NEAT1</i>-mediated paraspecklesManisha Yadav, Rachel J Harding, Tiantian Li, et al.
Scientific Reports|November 14, 2023
Gut inflammation associated with age and Alzheimer's disease pathology: a human cohort studyMargo B Heston, Kendra L Hanslik, Katie R Zarbock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2018
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune TherapiesJames J Harding, Subhiksha Nandakumar, Joshua Armenia, et al.
The Lancet. Oncology|June 5, 2023
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b studyJames J Harding, Jia Fan, Do-Youn Oh, et al.
Pageof 95